GenXone’s debut on the NewConnect market

On Tuesday, August 25, biotechnology company GenXone debut on the NewConnect market was announced. 3.295 million shares of four series with a nominal value of PLN 1 each will be marketed.

– We are entering the capital market as it is a natural development step for our business. We already have a solidly built structure of the company and activities that systematically build our revenues. We also have advantages that investors will appreciate. We are one of the few companies in the world that is accredited by Oxford Nanopore Technologies (ONT) – the creator of nanopore sequencing technology and a license enabling its commercial use – says Michał Kaszuba, president of the GenXone.

Since March, the team of the Molecular Diagnostics Laboratory has been carrying out tests to identify the SARS-CoV-2 coronavirus. The Company has already completed almost 30 thousand research.

Our research team is implementing a project that can help fighting the pandemic. As part of it, we learn about the genome of the SARS-CoV-2 coronavirus using nanopore sequencing. Thanks to this, we learn about the evolutionary and geographical origin of the coronaviruses detected in our molecular laboratory. This can be the basis for tracking a pandemic and preventing it. We have already learned 17 genomes of the coronavirus, and more are waiting in the queue – adds Kaszuba.